ESC
Primary Culture

Primary Neonatal Rat Ventricular Myocytes (NRVMs)

Isolation and culture of primary neonatal rat ventricular myocytes for cardiac contractility, electrophysiology, and cardiotoxicity screening. NRVMs provide a physiologically relevant platform that complements iPSC-derived cardiomyocyte models with native cardiac biology and spontaneous beating networks.

Isolation & Culture Cardiac Identity Contractility & Beating Calcium Transients Cardiotoxicity iPSC Cardiomyocytes
01

Neonatal Rat Ventricular Myocyte Isolation & Culture

Primary NRVMs were isolated from postnatal day 1–2 (P1–P2) Sprague-Dawley rat pups using serial enzymatic digestion. Hearts were excised, ventricles dissected, and tissue minced into ~1 mm pieces. Sequential digestion with collagenase type II (0.5 mg/mL) and pancreatin (0.6 mg/mL) in HBSS was performed in 5–7 rounds (15 min each, 37°C with gentle agitation). Supernatants were pooled, filtered (70 μm), and subjected to differential pre-plating (90 min) to deplete fibroblasts.

🧬
Culture Conditions
FIBRONECTIN DMEM/M199 5% HORSE SERUM
Purified myocytes were plated on fibronectin-coated (25 μg/mL) dishes at 1,500–2,500 cells/mm² in DMEM/M199 (4:1) supplemented with 5% horse serum, 100 μM BrdU (anti-fibroblast), and penicillin/streptomycin. Serum was reduced to 1% after 24 h to minimize fibroblast overgrowth. Spontaneous beating was typically observed by 48–72 h post-plating, with synchronous monolayer contractility established by day 4–5.

Isolation Yield & Quality Metrics

ParameterValueMethod
Yield per litter (10–12 pups)18.5 ± 3.2 × 106 cellsHemocytometer
Post-plating viability92.8 ± 2.4%Trypan blue
Cardiomyocyte purity (day 3)89.4 ± 3.2%cTnT+ / DAPI
Fibroblast contamination8.2 ± 2.6%Vimentin+ / DAPI
Onset of beating58 ± 12 hVisual inspection
Synchronous monolayer (day)4.2 ± 0.8Video analysis
18.5M
Cells per litter
89%
Cardiomyocyte purity (cTnT+)
~58 h
Onset of spontaneous beating
02

Cardiac Identity & Structural Characterization

NRVM identity and structural maturation were validated by immunocytochemistry for cardiac-specific markers, sarcomere organization analysis, and gene expression profiling.

Marker Expression Panel

MarkerTargetDay 1 (%)Day 3 (%)Day 5 (%)Day 7 (%)
cTnT (cardiac troponin T)Sarcomere72 ± 589 ± 391 ± 390 ± 3
α-ActininZ-disc68 ± 686 ± 492 ± 291 ± 3
MLC-2vVentricular58 ± 778 ± 584 ± 486 ± 3
NKX2-5Cardiac TF82 ± 488 ± 390 ± 289 ± 3
Connexin-43Gap junctions18 ± 552 ± 674 ± 482 ± 3
Sarcomere regularity (FFT)Organization0.32 ± 0.080.58 ± 0.060.74 ± 0.050.78 ± 0.04
92%
α-Actinin+ at day 5
82%
Connexin-43+ at day 7
0.78
Sarcomere regularity index
03

Contractility & Beat-Rate Analysis

Spontaneous beating was quantified using video-based motion analysis (MUSCLEMOTION) and impedance monitoring (xCELLigence CardioECR). NRVMs displayed stable, regular contractility with pharmacological responsiveness to chronotropic and inotropic agents.

Baseline Contractility Parameters

ParameterDay 3Day 5Day 7
Beat rate (BPM)124 ± 18156 ± 14168 ± 12
Beat regularity (CV%)18.4 ± 3.28.6 ± 1.85.2 ± 1.1
Contraction amplitude (AU)0.42 ± 0.080.68 ± 0.060.74 ± 0.05
Contraction velocity (μm/s)22.4 ± 4.638.2 ± 5.142.8 ± 4.8
Relaxation velocity (μm/s)18.6 ± 3.832.4 ± 4.236.1 ± 3.9

Pharmacological Responsiveness

AgentConc.Δ Beat Rate (%)Δ Amplitude (%)Reversible?
Isoproterenol1 μM+42 ± 6+28 ± 5Yes (full)
Carbachol10 μM−38 ± 5−12 ± 4Yes (full)
Nifedipine1 μM−24 ± 6−52 ± 7Yes (partial)
E-4031 (hERG block)100 nM−8 ± 3+6 ± 4Arrhythmia at 1 μM
Doxorubicin1 μM−62 ± 8−74 ± 6No (cytotoxic)
NRVM Beat-Rate Response to Isoproterenol
Dose-response curve at day 5. Mean ± SEM, n = 6 wells per concentration.
168 BPM
Baseline beat rate at day 7
+42%
Isoproterenol response
CV 5.2%
Beat regularity at day 7
04

Calcium Transient Profiling

Intracellular calcium dynamics were measured using Fluo-4 AM and Fura-2 AM loading with high-speed fluorescence imaging (100 fps). Calcium transient parameters were extracted using custom MATLAB scripts.

Calcium Transient Parameters (Day 5)

ParameterBaseline+ Iso (1 μM)+ Caff (10 mM)
Transient amplitude (ΔF/F0)2.4 ± 0.33.6 ± 0.44.8 ± 0.5
Time to peak (ms)68 ± 852 ± 642 ± 5
CTD50 (ms)142 ± 16108 ± 1282 ± 10
CTD90 (ms)286 ± 24218 ± 18164 ± 14
Decay tau (ms)124 ± 1486 ± 10
Transient frequency (Hz)2.6 ± 0.33.8 ± 0.4
2.4 ΔF/F0
Baseline Ca²+ amplitude
+50%
Iso-induced amplitude increase
286 ms
Baseline CTD90
05

Cardiotoxicity & Injury Biomarker Profiling

NRVMs were used to profile compound-induced cardiac injury using multi-parametric readouts including viability (CellTiter-Glo), LDH release, cardiac troponin I (cTnI) secretion, and functional beat-rate cessation.

Cardiotoxicity Reference Compound Panel

CompoundMechanismIC50 ViabilitycTnI EC50Beat Cessation
DoxorubicinTopoisomerase II0.8 ± 0.1 μM0.4 ± 0.08 μM1.2 μM
CisapridehERG block>30 μM>30 μMArrhythmia at 3 μM
TerfenadinehERG block12.4 ± 2.1 μM8.6 ± 1.4 μMArrhythmia at 1 μM
VerapamilCa²+ channel block>30 μM>30 μMCessation at 10 μM
Aspirin (neg. ctrl)COX inhibitor>100 μM>100 μMNo effect
0.8 μM
Doxorubicin IC50
5
Reference compounds profiled
4
Orthogonal readouts

NRVM Culture & Screening Workflow

01
Isolation
P1–P2 ventricular dissection. Collagenase/pancreatin digestion. Differential pre-plating for fibroblast depletion.
02
Culture & QC
Fibronectin-coated plating. BrdU anti-mitotic. ICC for cTnT, α-actinin, Cx43. Confirm beating by day 3.
03
Functional Assays
Video contractility (MUSCLEMOTION). Calcium transients (Fluo-4/Fura-2). Impedance (xCELLigence).
04
Screening
Compound dose-response. Multi-parametric readouts: viability, cTnI, LDH, beat cessation, arrhythmia detection.